Stay updated on Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the paclitaxel and pembrolizumab study is displayed with its study design, eligibility criteria, outcome measures, record dates, and associated documents.
    Difference
    55%
    Check dated 2026-11-11T17:09:55.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now shows revision v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-28T15:25:13.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    A banner announces NIH website transition updates and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-21T17:44:28.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-14T17:08:48.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.0 to v3.7.1, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T17:52:39.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error with a minimal header and a Home link. Most study-related content and navigational elements are absent on this page, indicating the record is not currently accessible.
    Difference
    20%
    Check dated 2026-09-23T20:55:54.000Z thumbnail image

Stay in the know with updates to Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.